menu
    • menu
    [{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Levosimendan","moa":"PDE3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Tenax Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injectable Solution","sponsorNew":"Tenax Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tenax Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Public Offering","leadProduct":"Levosimendan","moa":"PDE3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Tenax Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.01,"dosageForm":"","sponsorNew":"Tenax Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Tenax Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Levosimendan","moa":"Calcium sensitizer\/K-ATP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Tenax Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injectable Solution","sponsorNew":"Tenax Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tenax Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Levosimendan","moa":"PDE3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Tenax Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injectable Solution","sponsorNew":"Tenax Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tenax Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2020","type":"Public Offering","leadProduct":"Levosimendan","moa":"Calcium dependent Cardiac Troponin C","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Tenax Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.01,"dosageForm":"","sponsorNew":"Tenax Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Tenax Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Orion Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Levosimendan","moa":"PDE-3","graph1":"Neurology","graph2":"Phase III","graph3":"Orion Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Orion Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Orion Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Levosimendan","moa":"PDE3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Tenax Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injectable Solution","sponsorNew":"Tenax Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tenax Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Levosimendan","moa":"PDE3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Tenax Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injectable Solution","sponsorNew":"Tenax Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tenax Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Tenax Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Levosimendan","moa":"PDE3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injectable Solution","sponsorNew":"Orion Corporation \/ Tenax Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Orion Corporation \/ Tenax Therapeutics"},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Levosimendan","moa":"PDE3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Tenax Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injectable solution","sponsorNew":"Tenax Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tenax Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Levosimendan","moa":"Potassium ATP channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Tenax Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Tenax Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tenax Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Levosimendan","moa":"Potassium ATP channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Tenax Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Tenax Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tenax Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Orion Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Levosimendan","moa":"K-ATP channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Tenax Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tenax Therapeutics \/ Orion Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Tenax Therapeutics \/ Orion Corporation"},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Levosimendan","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Tenax Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tenax Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tenax Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Levosimendan","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Tenax Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tenax Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tenax Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Levosimendan","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Tenax Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Tenax Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tenax Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Levosimendan","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Tenax Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Tenax Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tenax Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Levosimendan","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Tenax Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Tenax Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tenax Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"Levosimendan","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Tenax Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.01,"dosageForm":"","sponsorNew":"Tenax Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"10","companyTruncated":"Tenax Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Orion Corporation","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Levosimendan","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Tenax Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Tenax Therapeutics \/ Orion Corporation","highestDevelopmentStatusID":"12","companyTruncated":"Tenax Therapeutics \/ Orion Corporation"},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"BVF Partners LP","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2024","type":"Private Placement","leadProduct":"Levosimendan","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Tenax Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Tenax Therapeutics \/ BVF Partners LP","highestDevelopmentStatusID":"14","companyTruncated":"Tenax Therapeutics \/ BVF Partners LP"},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"BVF Partners LP","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2024","type":"Private Placement","leadProduct":"Levosimendan","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Tenax Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Tenax Therapeutics \/ BVF Partners LP","highestDevelopmentStatusID":"14","companyTruncated":"Tenax Therapeutics \/ BVF Partners LP"}]

    Find Clinical Drug Pipeline Developments & Deals for dextrosimendan

    Menu

    dextrosimendan

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Orion Corporation

                            Finland
                            Skin Aging & Challenges
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Levosimendan

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : Tenax Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Tenax Therapeutics Gains North American Rights to Oral Levosimendan through Expanded License Agreement with Or...

                            Details : Amendment to the existing agreement gives Tenax rights to develop and commercialize in the United States and Canada an oral formulation of levosimendan for use with Type 2 pulmonary hypertension in heart failure patients with PH-HFpEF, or other heart rel...

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 15, 2020

                            Lead Product(s) : Levosimendan

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : Tenax Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            Fermion Orion Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Tenax Therapeutics

                            U.S.A arrow
                            Skin Aging & Challenges
                            Not Confirmed

                            Tenax Therapeutics

                            U.S.A arrow
                            Skin Aging & Challenges
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Levosimendan

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : BVF Partners LP

                            Deal Size : $100.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Tenax Therapeutics Closes $100M Private Placement to Accelerate Levosimendan Phase 3

                            Details : The funding will support the advancement of oral TNX-103 (levosimendan) phase 3 development program for the treatment of Pulmonary Hypertension Due to Heart Failure with Preserved Ejection Fraction.

                            Brand Name : TNX-103

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 12, 2024

                            Lead Product(s) : Levosimendan

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : BVF Partners LP

                            Deal Size : $100.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Tenax Therapeutics

                            U.S.A arrow
                            Skin Aging & Challenges
                            Not Confirmed

                            Tenax Therapeutics

                            U.S.A arrow
                            Skin Aging & Challenges
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Levosimendan

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : BVF Partners LP

                            Deal Size : $100.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Tenax Therapeutics Announces Oversubscribed $100 Million Private Placement

                            Details : The Company intends to use the net proceeds from the private placement to complete its ongoing late-stage clinical trial studies with Patients for the treatment of PH-HFpEF.

                            Brand Name : TNX-103

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 06, 2024

                            Lead Product(s) : Levosimendan

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : BVF Partners LP

                            Deal Size : $100.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Tenax Therapeutics

                            U.S.A arrow
                            Skin Aging & Challenges
                            Not Confirmed

                            Tenax Therapeutics

                            U.S.A arrow
                            Skin Aging & Challenges
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Levosimendan

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Orion Corporation

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Tevogen Bio Prepares to Launch Genetic Predisposition Study for TVGN 489 in Long COVID

                            Details : Under the license agreement, Tenax will be developing and commercializing the TNX-103 (levosimendan) for the treatment of pulmonary hypertension with heart failure with preserved ejection fraction.

                            Brand Name : TNX-103

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 20, 2024

                            Lead Product(s) : Levosimendan

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Orion Corporation

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Tenax Therapeutics

                            U.S.A arrow
                            Skin Aging & Challenges
                            Not Confirmed

                            Tenax Therapeutics

                            U.S.A arrow
                            Skin Aging & Challenges
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Levosimendan

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase III

                            Sponsor : Roth Capital Partners

                            Deal Size : $9.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Tenax Therapeutics Announces Pricing of Approximately $9 Million Public Offering

                            Details : The company intends to use the net proceeds for the clinical development of TNX-103 (levosimendan) for the treatment of pulmonary hypertension and heart failure with preserved ejection fraction.

                            Brand Name : TNX-103

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 08, 2024

                            Lead Product(s) : Levosimendan

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase III

                            Sponsor : Roth Capital Partners

                            Deal Size : $9.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Tenax Therapeutics

                            U.S.A arrow
                            Skin Aging & Challenges
                            Not Confirmed

                            Tenax Therapeutics

                            U.S.A arrow
                            Skin Aging & Challenges
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Levosimendan

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Of TNX-103

                            Details : TNX-103 (levosimendan) is in Phase 3 trials for pulmonary hypertension in heart failure with preserved ejection fraction, acting as a potassium ATP channel activator.

                            Brand Name : TNX-103

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 07, 2024

                            Lead Product(s) : Levosimendan

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Tenax Therapeutics

                            U.S.A arrow
                            Skin Aging & Challenges
                            Not Confirmed

                            Tenax Therapeutics

                            U.S.A arrow
                            Skin Aging & Challenges
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Levosimendan

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Tenax Therapeutics Announces FDA Clearance of IND for TNX-103 (oral levosimendan) for the Treatment of Pulmona...

                            Details : TNX-103 (levosimendan), is an oral, small molecule, unique potassium ATP channel activator and calcium sensitizer, being developed for Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction. There are currently no FDA approved treatme...

                            Brand Name : TNX-103

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 13, 2023

                            Lead Product(s) : Levosimendan

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Tenax Therapeutics

                            U.S.A arrow
                            Skin Aging & Challenges
                            Not Confirmed

                            Tenax Therapeutics

                            U.S.A arrow
                            Skin Aging & Challenges
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Levosimendan

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Tenax Therapeutics Achieves Major Milestone as USPTO Grants Notice of Allowance for U.S. Patent Application Co...

                            Details : TNX-103 (levosimendan), is an oral, small molecule, unique potassium ATP channel activator and calcium sensitizer, being developed for Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction. There are currently no FDA approved treatme...

                            Brand Name : TNX-103

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 31, 2023

                            Lead Product(s) : Levosimendan

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Tenax Therapeutics

                            U.S.A arrow
                            Skin Aging & Challenges
                            Not Confirmed

                            Tenax Therapeutics

                            U.S.A arrow
                            Skin Aging & Challenges
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Levosimendan

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Tenax Announces Issuance of U.S. Patent Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart F...

                            Details : TNX-101 (levosimendan) is a unique potassium ATP channel activator and calcium sensitizer that affects the heart and vascular system through multiple mechanisms of action.

                            Brand Name : TNX-101

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 22, 2023

                            Lead Product(s) : Levosimendan

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Tenax Therapeutics

                            U.S.A arrow
                            Skin Aging & Challenges
                            Not Confirmed

                            Tenax Therapeutics

                            U.S.A arrow
                            Skin Aging & Challenges
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Levosimendan

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Tenax Granted Notice of Allowance for U.S. Patent Application Covering Use of IV Levosimendan in Pulmonary Hyp...

                            Details : TNX-101 (levosimendan) is a unique potassium ATP channel activator and calcium sensitizer that affects the heart and vascular system through multiple mechanisms of action.

                            Brand Name : TNX-101

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 01, 2023

                            Lead Product(s) : Levosimendan

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth